Δημοσίευση

Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate.

ΤίτλοςInduction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate.
Publication TypeJournal Article
Year of Publication2019
AuthorsBoziki, M., Lagoudaki R., Melo P., Kanidou F., Bakirtzis C., Nikolaidis I., Grigoriadou E., Afrantou T., Tatsi T., Matsi S., & Grigoriadis N.
JournalJ Neurol Sci
Volume401
Pagination43-50
Date Published2019 Mar 29
ISSN1878-5883
Abstract

BACKGROUND: Induction of T-cell apoptosis constitutes a mechanism of action for Glatiramer Acetate (GA). We investigated whether activation of apoptotic T-cell death may be indicative of optimal treatment response in patients with relapsing-remitting Multiple Sclerosis (RRMS), with respect to radiological activity.
METHODS: We studied apoptotic markers on blood T-cells of forty patients with RRMS, 19 patients under GA and 21 patients under interferon-β (IFNβ), by flow cytometry. Patients were relapse-free and were further classified into optimal and sub-optimal responders based on radiological activity. Eighteen patients (8 patients under GA and 10 patients under IFNβ were additionally evaluated at a 12-month follow-up and were relapse- and radiological activity-free. For these patients, apoptosis was also evaluated by molecular techniques.
RESULTS: At inclusion, optimal responders to GA exhibited increased (23.6 ± 1.976) relative % frequency of CD4(+)AnnexinV(+)7AAD(-) T-cells, compared to sub-optimal responders (14.478 ± 1.204, p = 0.001). Similarly, relative % frequency of caspase-3(+) T-cells was 1.517 ± 0.436 versus 0.45 ± 0.149 (p = 0.041), respectively. Anti-apoptotic molecule bcl-2 showed an inverse pattern 4.532 ± 1.321 versus 13.094 ± 3.987, p = 0.044, respectively. These differences were not evident for IFNβ-treated patients.
CONCLUSIONS: T-cell apoptotic markers may be applied as a biomarker useful in evaluating optimal treatment response under GA, thus allowing for personalized treatment decisions.

DOI10.1016/j.jns.2019.03.030
Alternate JournalJ. Neurol. Sci.
PubMed ID31009931

Επικοινωνία

Γραμματεία Τμήματος Ιατρικής T.K. 54124 Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα social networks.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.